Tokyo, Japan

Sakari Sekine

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sakari Sekine: Innovator in Renal Disorder and Norovirus Research

Introduction

Sakari Sekine is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the fields of medical research and biotechnology. With a total of two patents to his name, Sekine's work focuses on innovative solutions for renal disorders and norovirus research.

Latest Patents

Sekine's latest patents include the "Utilization of cilastatin in inhibiting renal disorder." This invention aims to provide an inhibitor for renal injuries induced by iodinated contrast mediums, utilizing cilastatin or a pharmaceutically acceptable salt thereof. Another notable patent is the "Cultured transgenic cell allowing growth of norovirus, and use thereof." This invention addresses the stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal that allows murine norovirus (MNV) to grow across the barrier of host specificity in mammalian cells. This breakthrough enables a new screening method for norovirus-related drug development.

Career Highlights

Throughout his career, Sekine has worked with notable organizations such as Denka Company Limited and Niigata University. His experience in these institutions has contributed to his expertise in the field of medical research and innovation.

Collaborations

Sekine has collaborated with esteemed colleagues, including Akihiko Saito and Sawako Goto. These partnerships have further enhanced his research and development efforts.

Conclusion

Sakari Sekine is a distinguished inventor whose work in renal disorder treatment and norovirus research has the potential to make a significant impact in the medical field. His innovative patents reflect his dedication to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…